Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial)

Br J Haematol. 2019 May;185(3):573-578. doi: 10.1111/bjh.15551. Epub 2018 Aug 20.
No abstract available

Keywords: clinical trials; myeloma; myeloma therapy.

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Bortezomib / administration & dosage
  • Bortezomib / adverse effects
  • Dexamethasone / administration & dosage
  • Dexamethasone / adverse effects
  • Disease-Free Survival
  • Feasibility Studies
  • Follow-Up Studies
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / mortality
  • Panobinostat / administration & dosage*
  • Panobinostat / adverse effects
  • Recurrence
  • Survival Rate
  • Thalidomide / administration & dosage
  • Thalidomide / adverse effects

Substances

  • Thalidomide
  • Bortezomib
  • Dexamethasone
  • Panobinostat